CClinicalTrials.gg
CompletedNCT00544375Updated Nov 1, 2022

Measurements of Anemia and Physiologic Tissue Response to Blood Transfusions in VLBW Infants Using Quantitative NIRS

An observational study in Infant Development, sponsored by University of California, Irvine. Completed at 1 site in United States. Open to participants aged 1 Minute to 1 Month. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by University of California, Irvine · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
120
Ages
1 Minute to 1 Month
Sex
All
01

Study summary

The study quantified functional measures of red blood cell mass and oxygen in neonatal tissues using a non-invasive optical technique: near infrared optical spectroscopy . The study will determine the absolute concentrations of deoxygenated and oxygenated hemoglobin and calculate the tissue hemoglobin saturation and total hemoglobin concentration in viv. Near infrared optical spectroscopy technique use to assessing and defining tissue status in the anemic state and the tissue's response to transfusions, as well as in monitoring hemoglobin and hematocrit without pain or loss of blood.

Read the detailed description

Near infrared optical spectroscopy measurements will be conducted on the muscle, on the upper leg,arm or on the back, abdomen and the head. The actual location will depend upon the neonate position and size. A small soft plastic optical fibers probe will be placed to the select study areas and thhe time of the measurement will not exceed 1 hour.

NIRS measurements of hemoglobin and hemoglobin saturation in tissues before and after red-cell transfusions in VLBW infants will determine the true effect of the transfusions, and develop more substantial guidelines regarding indications for transfusion. The accuracy of conventional (invasive) measurements of Hb and Hct could be comparison with results from the NIRS technique and clinical usefulness of the NIRS technique could be evaluated by comparison with trends in conventionally measured values taking fluid status into account.

Near-infrared light does not ionize biological tissue and poses no significant health risk. Since water absorption is low within this spectral range, local heating of the tissue is also minimal. Burns and heat damage to the neonate are highly unlikely.

02

Conditions studied

  • Infant Development

Browse trials for

03

In context

Anemia

1,733 studies on the registry are indexed under Anemia; 246 are open to participants now.

This study's enrollment of 120 is below the median of 200 across 326 observational studies indexed under Anemia.

Browse Anemia studies →

Lead sponsor

University of California, Irvine is the lead sponsor of 466 studies on the registry; 96 are open to participants now.

Of its 41 completed or terminated interventional studies of FDA-regulated products, 30 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Minute to 1 Month
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

primary care clinic

Inclusion criteria

  • infants weighing less than 1500 grams at birth
  • infants receiving at least one packed red blood cell transfusion

Exclusion criteria

Exclusion Criteria:

  • neonates who are too unstable as determined by the clinicians for additional human contact
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
120 participants (actual)

Groups and cohorts

  • Neonatal Tissues

    Optical measurement neonatal tissues

    Device: Optical measurement

Interventions

  • DeviceOptical measurement

    Optical measurement neonatal tissues

06

What researchers measure

Primary outcomes

  1. Infant tissue's response to transfusions

    Time frame: 4 weeks

07

Study locations

1 site
  • Neonatal Intensive Care Unit, University of California Irvine
    Orange, California 92868, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00544375
Lead sponsor
University of California, Irvine
Collaborators
Beckman Laser Institute University of California Irvine
Responsible party
Beckman Laser Institute and Medical Center (Feizal Waffarn, M.D, University of California, Irvine) — Principal investigator
First posted
Oct 16, 2007
Start date
Jun 2002
Primary completion
Sep 2008
Completion
Sep 2008
Last update
Nov 1, 2022

Study contacts

Feizal Waffarn, M.D
principal investigator · Beckman Laser Institute University of California Irvine
Bruce Tromberg, PhD
study director · Beckman Laser Institute University of California Irvine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion